Skip to main content
Premium Trial:

Request an Annual Quote

Quidel Acquires Diagnostic Hybrids for $130M

NEW YORK (GenomeWeb News) – Point-of-care diagnostic test provider Quidel said today that it has agreed to acquire Diagnostic Hybrids for approximately $130 million.

Diagnostic Hybrids, based in Athens, Ohio, manufactures and sells direct fluorescent in vitro diagnostic assays used in hospital and reference laboratories for a variety of diseases, including viral respiratory infections, herpes, chlamydia, and thyroid disease.

Quidel, based in San Diego, said that Diagnostic Hybrids' assays will broaden its current portfolio into complementary non-seasonal infectious and autoimmune diseases and help diversify its revenue base.

"In the hospital segment, fluorescent assays fill a customer need that is not met by point-of-care lateral flow or molecular diagnostics assays," Douglas Bryant, Quidel's president and CEO, said in a statement.

Bryant added that the combined company will offer "a continuum of diagnostic tests for triaging patients, confirming diagnoses, and providing actionable results to improve patient care."

Quidel said that it plans to operate Diagnostic Hybrids as a separate subsidiary, and that it expects the acquisition to close in current quarter.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.